All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD276 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD276. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD276 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Melanoma.
CAR Construction : BRCA84D-4-1BB-CD3ζ Fig.1 Cytokine release assay. Summary of cytokine release of GM-CSF, IFNγ, IL2, MCP1, and TNF measured by ELISA from UT and B7H3 CAR-T cells co-cultured with CHLA255 NBL cells at 1:1 effector:target ratio. Moghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L., Bassiri, H., ... & Asgharzadeh, S. (2021). Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature communications, 12(1), 1-15. |
CAR Construction : BRCA84D-4-1BB-CD3ζ Fig.2 Cytotoxicity assay in vitro. Kinetics of mean cytotoxicity of UT and B7H3 CAR-T using live-cell imaging (enumeration of GFP+ tumor cells) against NBL cell lines (CHLA255, LAN5, and SK-N-BE (2)) at indicated E:T ratios. Moghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L., Bassiri, H., ... & Asgharzadeh, S. (2021). Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature communications, 12(1), 1-15. |
CAR Construction : BRCA84D-4-1BB-CD3ζ Fig.3 Evaluation of antitumor efficiency in vivo. Representative bioluminescence images of CHLA255 tumor growth upon intravenous (i.v.) injection into NSG mice (1 × 106 cells/mouse) and treatment 14 days later with i.v. injection of B7H3 CAR-T or UT cells (1 × 10^7 on day 14) Moghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L., Bassiri, H., ... & Asgharzadeh, S. (2021). Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature communications, 12(1), 1-15. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD276 (BRCA84D) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP7466). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION